From Retigabine to Azetukalner: Reviving Voltage‐Gated Potassium Channels for Epilepsy Therapy
Archiv der Pharmazie · 2026-06 · 359 (6)
DOI: 10.1002/ardp.70279 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 03.07.2026. Verfasst von Pascal Rosendahl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Carbamates, Anticonvulsants, Phenylenediamines, Epilepsy. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).
Abstract (Originalsprache)
Heterotetrameric K V 7.2/3 potassium channels were retrospectively identified as the target of the analgesic flupirtine and the antiepileptic retigabine (ezogabine). Clinical utility of these agents ended after decades or 6 years, respectively, before their full scope was explored. Market withdrawals in 2017 and 2018 hampered research in other medical fields and left a gap for researchers using these compounds off‐label in experimental indications and for patients with K V 7.2/3 malfunctions. Failure of these drugs might be regarded as a reason to abandon this class of compounds, due to the notion that toxicity might be a class effect and to competitive markets. Yet, evidence accumulated that the toxicity of both compounds is not an inherent property of modulators of K V 7.2/3 channels, but rather the result of an oxidation‐sensitive metabophore/toxicophore. Second, epilepsy associated with K V 7.2/3 channelopathies might rationally be addressed best with modulators of this validated drug target. Employing retrometabolic drug design to remodel the enzyme‐labile carbamate structure and the central highly substituted ring, azetukalner (formerly encukalner, XEN1101) emerged from the unlucky forerunners. This structural analog of retigabine exhibits improved metabolic stability, increased potency, and enhanced blood–brain barrier penetration compared with its predecessor. This review details the synthesis, physicochemical properties, and clinical results of azetukalner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
ORCID-Profile: Pascal Rosendahl, Lukas Schulig, Andreas Link
Förderung
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
Zitieren
APA
Rosendahl, P., Schulig, L., & Link, A. (2026). From Retigabine to Azetukalner: Reviving Voltage‐Gated Potassium Channels for Epilepsy Therapy. Archiv der Pharmazie, 359(6). https://doi.org/10.1002/ardp.70279
Vancouver
Rosendahl P, Schulig L, Link A. From Retigabine to Azetukalner: Reviving Voltage‐Gated Potassium Channels for Epilepsy Therapy. Archiv der Pharmazie. 2026;359(6). doi:10.1002/ardp.70279
BibTeX
@article{Rosendahl2026,
author = {Rosendahl, Pascal and Schulig, Lukas and Link, Andreas},
title = {From Retigabine to Azetukalner: Reviving Voltage‐Gated Potassium Channels for Epilepsy Therapy},
journal = {Archiv der Pharmazie},
year = {2026},
volume = {359},
number = {6},
doi = {10.1002/ardp.70279}
}
EUVIMED